The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

January 19, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

FDA Accepts Application for Subcutaneous Rituximab

You Might Also Like
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis
Explore This Issue
January 2017
Also By This Author
  • Drug Updates

The FDA has accepted the biologics license application (BLA) for the subcutaneous formulation of rituximab (Rituxan), with an action date of June 26, 2017.3 The BLA was accepted subsequent to updated study results from the Phase 3 SABRINA trial, which compared subcutaneous and intravenous rituximab in previously untreated follicular lymphoma oncology patients. Data from this study were presented at the American Society of Hematology Annual Meeting, Dec. 3–6.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Etanercept Approved for Pediatric Plaque Psoriasis

The FDA has approved the supplemental BLA for etanercept (Enbrel) to treat pediatric patients (ages 4–17) with chronic moderate to severe plaque psoriasis.4 This agent is the first systemic treatment for patients at this age and with this condition. The approval was based on results from a one-year, Phase 3 study along with a five-year, open-label extension study, which evaluated the efficacy and safety of etanercept in patients aged 4–17 with chronic moderate to severe plaque psoriasis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Adverse events seen in these pediatric patients were similar to those seen in prior studies in adults with moderate to severe plaque psoriasis.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A Phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016; 387(10031):1921–1927.
  2. Adler S, Reichenbach S, Kuchen S, et al. Termination of tocilizumab treatment in giant cell arteritis: Follow-up of patients after the RCT (ClinicalTrials.gov registration number: NCT01450137) [abstract]. Arthritis Rheumatol. 2016;68 (Suppl 10).
  3. Genentech Inc. News release: Genentech showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting. 2016 Nov 3.
  4. Amgen Inc. News release: FDA approves expanded use of Enbrel (etanercept) to treat children with chronic moderate to severe plaque psoriasis. FirstWord Pharma. 2016 Nov 4.

Editor’s note: These briefs were previously published on our website.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Approval, drug, etanercept, FDA, Giant Cell Arteritis, outcome, patient care, Quality, relapse, Research, rheumatology, rituximab, Safety, trialIssue: January 2017

You Might Also Like:
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis
  • Updates on Giant Cell Arteritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)